Hepatitis C virus NS3 protease inhibitors: Large, flexible molecules of peptide origin show satisfactory permeability across Caco-2 cells

European Journal of Pharmaceutical Sciences

Volumn 38, Issue 5, 2009, Pages 556-563

  Bergström, Christel A S ^a   Bolin, Sara ^a   Artursson, Per ^a   Rönn, Robert ^a   Sandström, Anja ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

Acyl sulfonamide; Caco 2; Efflux; HCV NS3 protease inhibitors; Membrane permeability; Peptide; Physicochemical properties; Transport rate

Indexed keywords

ELACRIDAR; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 1; PROTEINASE INHIBITOR;

APICAL MEMBRANE; ARTICLE; BASOLATERAL MEMBRANE; CELL MEMBRANE PERMEABILITY; CELL STRAIN CACO 2; CONTROLLED STUDY; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG PENETRATION; DRUG STRUCTURE; DRUG TRANSPORT; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; INTESTINE ABSORPTION; INTESTINE MUCOSA PERMEABILITY; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL;

ACRIDINES; ADENOSINE TRIPHOSPHATASES; ANTIVIRAL AGENTS; CACO-2 CELLS; CELL MEMBRANE PERMEABILITY; HUMANS; INTESTINAL ABSORPTION; P-GLYCOPROTEIN; PEPTIDES; SERINE PROTEINASE INHIBITORS; TETRAHYDROISOQUINOLINES; VIRAL NONSTRUCTURAL PROTEINS;

EID: 70449533153     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2009.10.004     Document Type: Article

References (47)

1. Artursson P. Epithelial transport of drugs in cell culture. I: A model for studying the passive diffusion of drugs over intestinal absorptive (Caco-2) cells. J. Pharm. Sci. 79 (1990) 476-482
2. Aszalos A. Drug-drug interactions affected by the transporter protein, P-glycoprotein (ABCB1, MDR1). II. Clinical aspects. Drug Discov. Today 12 (2007) 838-843
3. Behrens I., and Kissel T. Do cell culture conditions influence the carrier-mediated transport of peptides in Caco-2 cell monolayers?. Eur. J. Pharm. Sci. 19 (2003) 433-444
4. Bergström C.A.S., Strafford M., Lazorova L., Avdeef A., Luthman K., and Artursson P. Absorption classification of oral drugs based on molecular surface properties. J. Med. Chem. 46 (2003) 558-570
5. Bergström C.A.S., Wassvik C.M., Johansson K., and Hubatsch I. Poorly soluble marketed drugs display solvation limited solubility. J. Med. Chem. 50 (2007) 5858-5862
6. Borst P., Evers R., Kool M., and Wijnholds J. A family of drug transporters: the multidrug resistance-associated proteins. J. Natl. Cancer Inst. 92 (2000) 1295-1302
7. Burton P.S., Conradi R.A., Hilgers A.R., Ho N.F.H., and Maggiora L.L. The relationship between peptide structure and transport across epithelial cell monolayers. J. Contr. Rel. 19 (1992) 87-98
8. Cole S.P., Bhardwaj G., Gerlach J.H., Mackie J.E., Grant C.E., Almquist K.C., Stewart A.J., Kurz E.U., Duncan A.M., and Deeley R.G. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258 (1992) 1650-1654
9. Conradi R.A., Hilgers A.R., Ho N.F., and Burton P.S. The influence of peptide structure on transport across Caco-2 cells. Pharm. Res. 8 (1991) 1453-1460
10. Conradi R.A., Hilgers A.R., Ho N.F., and Burton P.S. The influence of peptide structure on transport across Caco-2 cells. II. Peptide bond modification which results in improved permeability. Pharm. Res. 9 (1992) 435-439
11. de Bruin M., Miyake K., Litman T., Robey R., and Bates S.E. Reversal of resistance by GF120918 in cell lines expressing the ABC half-transporter MXR. Cancer Lett. 146 (1999) 117-126
12. Didziapetris R., Japertas P., Avdeef A., and Petrauskas A. Classification analysis of P-glycoprotein substrate specificity. J. Drug Target. 11 (2003) 391-406
13. Dressman J.B., Vertzoni M., Goumas K., and Reppas C. Estimating drug solubility in the gastrointestinal tract. Adv. Drug Deliv. Rev. 59 (2007) 591-602
14. Feld J.J., and Hoofnagle J.H. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 436 (2005) 967-972
15. Fojo A.T., Ueda K., Slamon D.J., Poplack D.G., Gottesman M.M., and Pastan I. Expression of a multidrug-resistance gene in human tumors and tissues. Proc. Natl. Acad. Sci. U.S.A. 84 (1987) 265-269
16. Gatlik-Landwojtowicz E., Aanismaa P., and Seelig A. Quantification and characterization of P-glycoprotein-substrate interactions. Biochemistry 45 (2006) 3020-3032
17. Gupta A., Zhang Y., Unadkat J.D., and Mao Q. HIV protease inhibitors are inhibitors but not substrates of the human breast cancer resistance protein (BCRP/ABCG2). J. Pharmacol. Exp. Ther. 310 (2004) 334-341
18. Homolya L., Hollo Z., Germann U.A., Pastan I., Gottesman M.M., and Sarkadi B. Fluorescent cellular indicators are extruded by the multidrug resistance protein. J. Biol. Chem. 268 (1993) 21493-21496
19. Jonker J.W., Merino G., Musters S., van Herwaarden A.E., Bolscher E., Wagenaar E., Mesman E., Dale T.C., and Schinkel A.H. The breast cancer resistance protein BCRP (ABCG2) concentrates drugs and carcinogenic xenotoxins into milk. Nat. Med. 11 (2005) 127-129
20. Kim W.R. Global epidemiology and burden of Hepatitis C. Microbes Infect. 4 (2002) 1219-1225
21. Li C., Nair L., Liu T., Li F., Pichardo J., Agrawal S., Chase R., Tong X., Uss A.S., Bogen S., Njoroge F.G., Morrison R.A., and Cheng K.C. Correlation between PAMPA permeability and cellular activities of hepatitis C virus protease inhibitors. Biochem. Pharmacol. 75 (2008) 1186-1197
22. Lipka E., Crison J., and Amidon G.L. Transmembrane transport of peptide type compounds: prospects for oral delivery. J. Contr. Rel. 39 (1996) 121-129
23. Matsson P., Pedersen J.M., Norinder U., Bergström C.A.S., and Artursson P. Identification of novel specific and general inhibitors of the three major human ATP binding cassette transporters P-gp, BCRP and MRP2 among registered drugs. Pharm. Res. 26 (2009) 1816-1831
24. Neuhoff S., Ungell A.L., Zamora I., and Artursson P. pH-dependent bidirectional transport of weakly basic drugs across Caco-2 monolayers: implications for drug-drug interactions. Pharm. Res. 20 (2003) 1141-1148
25. Neuhoff S., Ungell A.L., Zamora I., and Artursson P. pH-Dependent passive and active transport of acidic drugs across Caco-2 cell monolayers. Eur. J. Pharm. Sci. 25 (2005) 211-220
26. Pedersen J.M., Matsson P., Bergström C.A.S., Norinder U., Hoogstraate J., and Artursson P. Prediction and identification of drug interactions with the human ATP binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2). J. Med. Chem. 51 (2008) 3275-3287
27. Prime-Chapman H.M., Fearn R.A., Cooper A.E., Moore V., and Hirst B.H. Differential multidrug resistance-associated protein 1 through 6 isoform expression and function in human intestinal epithelial Caco-2 cells. J. Pharmacol. Exp. Ther. 311 (2004) 476-484
28. Rönn R., Gossas T., Sabnis Y.A., Daoud H., Åkerblom E., Danielson U.H., and Sandström A. Evaluation of a diverse set of potential P1 carboxylic acid bioisosteres in hepatitis C virus NS3 protease inhibitors. Bioorg. Med. Chem. 15 (2007) 4057-4068
29. Rönn R., Sabnis Y.A., Gossas T., Åkerblom E., Danielson U.H., Hallberg A., and Johansson A. Exploration of acyl sulfonamides as carboxylic acid replacements in protease inhibitors of the hepatitis C virus full-length NS3. Bioorg. Med. Chem. 14 (2006) 544-559
30. Rönn R., and Sandström A. New developments in the discovery of agents to treat hepatitis C. Curr. Top. Med. Chem. 8 (2008) 533-562
31. Sai Y., Kaneko Y., Ito S., Mitsuoka K., Kato Y., Tamai I., Artursson P., and Tsuji A. Predominant contribution of organic anion transporting polypeptide OATP-B (OATP2B1) to apical uptake of estrone-3-sulfate by human intestinal Caco-2 cells. Drug Metab. Dispos. 34 (2006) 1423-1431
32. Schaaf T.K., and Hess H.J. Synthesis and biological activity of carboxyl-terminus modified prostaglandin analogues. J. Med. Chem. 22 (1979) 1340-1346
33. Schinkel A.H., and Joncker J.W. Mammalian drug efflux transporters of the ATP bindning cassette (ABC) family: an overview. Adv. Drug Deliv. Rev. 55 (2003) 3-29
34. Seelig A., and Landwojtowicz E. Structure-activity relationship of P-glycoprotein substrates and modifiers. J. Pharm. Sci. 12 (2000) 31-40
35. Shapiro A.B., Corder A.B., and Ling V. P-glycoprotein-mediated Hoechst 33342 transport out of the lipid bilayer. Eur. J. Biochem. 250 (1997) 115-121
36. Shirota F.N., Nagasawa H.T., Kwon C.H., and DeMaster E.G. N-acetylcyanamide, the major urinary metabolite of cyanamide in rat, rabbit, dog, and man. Drug Metab. Dispos. 12 (1984) 337-344
37. Stenberg P., Luthman K., and Artursson P. Prediction of membrane permeability to peptides from calculated dynamic molecular surface properties. Pharm. Res. 16 (1999) 205-212
38. Taipalensuu J., Tavelin S., Lazorova L., Svensson A.C., and Artursson P. Exploring the quantitative relationship between the level of MDR1 transcript, protein and function using digoxin as a marker of MDR1-dependent drug efflux activity. Eur. J. Pharm. Sci. 21 (2004) 69-75
39. Taipalensuu J., Törnblom H., Lindberg G., Einarsson C., Sjöqvist F., Melhus H., Garberg P., Sjöström B., Lundgren B., and Artursson P. Correlation of gene expression of ten drug efflux proteins of the ATP-binding cassette transporter family in normal human jejunum and in human intestinal epithelial Caco-2 cell monolayers. J. Pharmacol. Exp. Ther. 299 (2001) 164-170
40. Tavelin S., Gråsjö J., Taipalensuu J., Ocklind G., and Artursson P. Applications of epithelial cell culture in studies of drug transport. Methods Mol. Biol. 72 (2002) 188-233
41. Thiebaut F., Tsuruo T., Hamada H., Gottesman M.M., Pastan I., and Willingham M.C. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc. Natl. Acad. Sci. U.S.A. 84 (1987) 7735-7738
42. Thiebaut F., Tsuruo T., Hamada H., Gottesman M.M., Pastan I., and Willingham M.C. Immunohistochemical localization in normal tissues of different epitopes in the multidrug transport protein P170: evidence for localization in brain capillaries and crossreactivity of one antibody with a muscle protein. J. Histochem. Cytochem. 37 (1989) 159-164
43. Thompson A., Patel K., Tillman H., and McHutchison J.G. Directly acting antivirals for the treatment of patients with hepatitis C infection: a clinical development update addressing key future challenges. J. Hepatol. 50 (2009) 184-194
44. Thornber C.W. Isosterism and molecular modifications in drug design. Chem. Soc. Rev. 8 (1979) 563-580
45. Yee Y.K., Bernstein P.R., Adams E.J., Brown F.J., Cronk L.A., Hebbel K.C., Vacek E.P., Krell R.D., and Snyder D.W. A novel series of selective leukotriene antagonists: exploration and optimization of the acidic region in 1,6-disubstituted indoles and indazoles. J. Med. Chem. 33 (1990) 2437-2451
46. Yang C.Y., Dantzig A.H., and Pidgeon C. Intestinal peptide transport systems and oral drug availability. Pharm. Res. 16 (1999) 1331-1343
47. Zhang Y., Gupta A., Wang H., Zhou L., Vethanayagam R.R., Unadkat J.D., and Mao Q. BCRP transports dipyridamole and is inhibited by calcium channel blockers. Pharm. Res. 22 (2005) 2023-2034